January 26, 2024

Reminder of Recommendations for Seasonal Administration of Maternal RSV Vaccine

The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) recommend the RSV vaccination (Pfizer Abrysvo) for pregnant people during 32–36 weeks gestation using seasonal administration to protect infants against RSV-associated lower respiratory tract disease (LRTD) after birth. In most of the continental United States, the RSV vaccine should be given to pregnant people from September 1 through January 31, regardless of year-to-year circulation, when infants would be born during increased RSV activity, and the vaccination would provide the most benefits to the infant against RSV-associated LRTD after birth. Jurisdictions that have different RSV seasonality from most of the continental United States, such as Alaska, southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands, and the U.S. Virgin Islands, may consider RSV vaccination of pregnant people after January 31. Infants born to unvaccinated mothers should receive nirsevimab, a long-acting monoclonal antibody that provides immediate protection to the infant against RSV-associated LRTD.

Recommendations for Healthcare Providers on the Seasonal Administration of the RSV Vaccine (Pfizer Abrysvo)

In most of the continental United States, administer the maternal RSV vaccine (Pfizer Abrysvo) from September 1 through January 31.
- Healthcare providers who administer the RSV vaccine to pregnant people after January 31 should encourage patients to check with their insurance plans on coverage details, as coverage and cost-sharing by private insurance plans may vary after January 31. Providers should consider submitting an insurance test claim to estimate out-of-pocket costs.
In jurisdictions where seasonality differs from most of the continental United States, such as Alaska, southern Florida, Guam, Hawaii, Puerto Rico, the U.S.-affiliated Pacific Islands, and the U.S. Virgin Islands, healthcare providers should follow state, local, or territorial guidance on timing of administering the RSV vaccine (Pfizer Abrysvo) for pregnant people.
CDC recommends protecting all infants against RSV-associated LRTD through either the RSV vaccine for pregnant people (Pfizer Abrysvo) or infant receipt of nirsevimab. Administration of both products is not needed for most infants.
- For infants age less than 8 months born to unvaccinated mothers, healthcare providers should administer nirsevimab from October 1 through March 31; however, healthcare providers can administer nirsevimab outside of this timeframe based on local epidemiology

For More Information:

The Office of Emergency Risk Communication in the Office of Communications is responsible for the management of all COCA Products.

For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov

Clinician Outreach and Communication Activity—resources for healthcare providers

COCA RSS Feed—subscribe to be notified of conference calls, updates, and CDC guidance for health providers

Crisis & Emergency Risk Communication Training—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication

Health Alert Network—CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories

	CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.

Centers for Disease Control and Prevention 1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348 Questions or Problems \| Unsubscribe